SCHEMBL5879293

SCHEMBL5879293

O=C1C=C(c2c[nH]c3cccc(O)c23)C(=O)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 6/20 0.43
HTR1A P08908 3/20 0.43
CCNB2 O95067 2/20 0.43
CDK1 P06493 2/20 0.43
CCNB1 P14635 2/20 0.43
PRKACA P17612 2/20 0.43
PRKACG P22612 2/20 0.43
PRKACB P22694 2/20 0.43
CDK2 P24941 2/20 0.43
CCNB3 Q8WWL7 2/20 0.43
PDPK1 O15530 1/20 0.43
CCNT1 O60563 1/20 0.43
CCNA2 P20248 1/20 0.43
GSK3B P49841 1/20 0.43
CDK9 P50750 1/20 0.43
CCNA1 P78396 1/20 0.43
CDK5 Q00535 1/20 0.43
SLC6A3 Q01959 1/20 0.43
CDK5R1 Q15078 1/20 0.43
GAA P10253 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879234 0.82 GPR84 (0.44) CCNB2CDK1CCNB1PRKACAPRKACG
SCHEMBL5879276 0.82 GPR84 (0.44) CCNB2CDK1CCNB1PRKACAPRKACG
SCHEMBL5879188 0.82 FFAR1 (0.44) HTR2BHTR1ACCNB2CDK1CCNB1
SCHEMBL5879280 0.82 CYP2A6 (0.45) CCNB2CDK1CCNB1PRKACAPRKACG
SCHEMBL5879162 0.82 CLK1 (0.45) HTR2BHTR1ACCNB2CDK1CCNB1
SCHEMBL5879149 0.79 HTR2A (0.47) HTR2BHTR1ACDK2CCNA2GSK3B
SCHEMBL5879296 0.78 CLK1 (0.49) CCNB2CDK1CCNB1PRKACAPRKACG
SCHEMBL29771997 0.75 PRKCB (0.65) CCNB2CDK1CCNB1PRKACAPRKACG
SCHEMBL2193383 0.75 PRKCB (0.65) CCNB2CDK1CCNB1PRKACAPRKACG
SCHEMBL31214628 0.74 PTPN1 (0.50) GSK3BKDM4EMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 HTR2B 2815/4885HTR1A 1444/4885CCNB2 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.